Status:
COMPLETED
Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection
Lead Sponsor:
Karolinska Institutet
Collaborating Sponsors:
Karolinska University Hospital
Conditions:
Glioblastoma Multiforme
Cytomegalovirus Infection
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to investigate if treatment of CMV infection by antiviral drug Valcyte (R) affects the clinical outcome of glioblastoma multiforme in patients with local CMV infection in ...
Eligibility Criteria
Inclusion
- Glioblastoma grade IV
- Cytomegalovirus detected in tumor
- At least 90% resection of tumor
Exclusion
- Decreased kidney function
- Pregnancy
- Neutropenia
- Thrombocytopenia
- Patient not tolerating the drug
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00400322
Start Date
August 1 2006
End Date
June 1 2008
Last Update
March 1 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of neurosurgery, Karolinska University Hospital
Solna, Stockholm County, Sweden, 17176
2
Department of Oncology, Norrland University Hospital
Umeå, Sweden, 901 85
3
Department of Oncology, Akademiska Hospital
Uppsala, Sweden, 751 85